Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Expression of B7-H1, a costimulating glycoprotein in the B7 family, is normally restricted to macrophage-lineage cells, providing a potential costimulatory signal source for regulation of T cell activation. In contrast, aberrant expression of B7-H1 by tumor cells has been implicated in impairment of T cell function and survival, resulting in defective host antitumoral immunity. The relationship between tumor-associated B7-H1 and clinical cancer progression is unknown. Herein, we report B7-H1 expression by both renal cell carcinoma (RCC) tumors of the kidney and RCC tumor-infiltrating lymphocytes. In addition, our analysis of 196 clinical specimens reveals that patients harboring high intratumoral expression levels of B7-H1, contributed by tumor cells alone, lymphocytes alone, or tumor and/or lymphocytes combined, exhibit aggressive tumors and are at markedly increased risk of death from RCC. In fact, patients with high tumor and/or lymphocyte B7-H1 levels are 4.5 times more likely to die from their cancer than patients exhibiting low levels of B7-H1 expression (risk ratio 4.53; 95% confidence interval 1.94–10.56; P < 0.001.) Thus, our study suggests a previously undescribed mechanism whereby RCC may impair host immunity to foster tumor progression. B7-H1 may prove useful as a prognostic variable for RCC patients both pre- and posttreatment. In addition, B7-H1 may represent a promising target to facilitate more favorable responses in patients who require immunotherapy for treatment of advanced RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequent human studies have consistently shown that PD-L1 and PD-L2 expression not only increases in cancerous tissues but is also linked to poor disease prognosis in many cancer types (50)(51)(52)(53)(54)(55)(56).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [50]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Self-citationIwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Self-citationPhan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
The Heidelberg classification of renal cell tumours
Kovacs, G., Akhtar, M., Beckwith, B. J., Bugert, P., Cooper, C. S., Delahunt, B., Eble, J. N., Fleming, S., Ljungberg, B., Medeiros, L. J., et al. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199710)183:2<131::aid-path931>3.0.co;2-g · Cited by 1,354
FRANK, I., BLUTE, M. L., CHEVILLE, J. C., LOHSE, C. M., WEAVER, A. L., & ZINCKE, H. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64153-5 · Cited by 1,175
Self-citationComparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma
Cheville, J. C., Lohse, C. M., Zincke, H., Weaver, A. L., & Blute, M. L. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200305000-00005 · Cited by 1,087
Self-citationHodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
THE CHANGING NATURAL HISTORY OF RENAL CELL CARCINOMA
PANTUCK, A. J., ZISMAN, A., & BELLDEGRUN, A. S. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65640-6 · Cited by 882
Research works printed but not linked: 13
- Strome, S.-E., Dong, H., Tamura, H., Voss, S.-G., Flies, D.-B., Tamada, K., Salomao, D., Cheville, J.-C, Hirano, F., Lin, W., et al. (2003) Cancer Res. 63, 6501–6505. [PubMed] [Google Scholar]
- Graham, S., Babayan, R.-K., Lamm, D.-L., Sawczuk, I., Ross, S.-D., Lavin, P.-T., Osband, M.-E. & Krane, R.-J. (1993) Semin. Urol. 11, 27–34. [PubMed] [Google Scholar]
- Krejci, K.-G., Markiewicz, M.-A. & Kwon, E.-D. (2003) J. Urol. 171, 870–876. [DOI] [PubMed] [Google Scholar]
- Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H. & Ohtani, H. (2001) Cancer Res. 61, 5132–5136. [PubMed] [Google Scholar]
- Storkel, S., Eble, J.-N., Adlakha, K., Amin, M., Blute, M.-L., Bostwick, D.-G., Darson, M., Delahunt, B. & Iczkowski, K. (1997) Cancer 80, 987–989. [DOI] [PubMed] [Google Scholar]
- Wintterle, S., Schreiner, B., Mitsdoerffer, M., Schneider, D., Chen, L., Meyermann, R., Weller, M. & Wiendl, H. (2003) Cancer Res. 63, 7462–7467. [PubMed] [Google Scholar]
- Uzzo, R.-G., Rayman, P., Kolenko, V., Clark, P.-E., Bloom, T., Ward, A.-M., Molto, L., Tannenbaum, C., Worford, L.-J, Bukowski, R.-M., et al. (1999) Clin. Cancer Res. 5, 1219–1229. [PubMed] [Google Scholar]
- Alexander, J.-P., Kudoh, S., Melsop, K.-A., Hamilton, T.-A., Edinger, M.-G., Tubbs, R.-R., Sica, D., Tuason, L., Klein, E., Bukowski, R., et al. (1993) Cancer. Res. 53, 1380–1387. [PubMed] [Google Scholar]
- Li, X., Liu, J., Park, J.-K., Hamilton, T.-A., Rayman, P., Klein, E., Edinger, M., Tubbs, R., Bukowski, R. & Finke, J. (1994) Cancer Res. 54, 5424–5429. [PubMed] [Google Scholar]
- Kudoh, S., Redovan, C., Rayman, P., Edinger, M., Tubbs, R.-R., Novick, A., Finke, J.-H. & Bukowski, R.-M. (1997) J. Immunol. 20, 479–487. [DOI] [PubMed] [Google Scholar]
- Motzer, R.-J. (2003) Crit. Rev. Oncol. Hematol. 46S, s33–s39. [DOI] [PubMed] [Google Scholar]
- Hofmockel, G., Tsatalpas, P., Muller, H., Dammrich, J., Poot, M., Maurer-Schultze, B., Muller-Hermelink, H.-K., Frohmuller, H.-G. & Bassukas, I.-D. (1995) Cancer 76, 296–306. [DOI] [PubMed] [Google Scholar]
- Shimazui, T., Oosterwijk, E., Akaza, H., Bringuier, P., Ruijter, E., van Berkel, H., Wakka, J.-O., van Bokhoven, A., Debruyne, F.-M. & Schalken, J.-A. (1998) Clin. Cancer Res. 4, 2419–2424. [PubMed] [Google Scholar]
Cited by
Items 301–400 of 796
Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy
Wu, X., Li, Y., Liu, X., Chen, C., Harrington, S. M., Cao, S., Xie, T., Pham, T. T., Mansfield, A. S., Yan, Y., et al. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e01039 · Cited by 59
Self-citationVelilla, P. A., Montoya, C. J., Hoyos, A., Moreno, M. E., Chougnet, C. A., & Rugeles, M. T. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.11.004 · Cited by 59
Maghrouni, A., Givari, M., Jalili‐Nik, M., Mollazadeh, H., Bibak, B., Sadeghi, M. M., Afshari, A. R., Johnston, T. P., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107403 · Cited by 61
Fukuda, T., Kamai, T., Masuda, A., Nukui, A., Abe, H., Arai, K., & Yoshida, K. (2016) · Cancer Medicine · doi:10.1002/cam4.754 · Cited by 57
Hendriks, D., Choi, G., de Bruyn, M., Wiersma, V. R., & Bremer, E. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2016.10.002 · Cited by 67
Immunologic Checkpoints Blockade in Renal Cell, Prostate, and Urothelial Malignancies
Bracarda, S., Altavilla, A., Hamzaj, A., Sisani, M., Marrocolo, F., Buono, S. D., & Danielli, R. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.004 · Cited by 57
Qiu, J., Cheng, Z., Jiang, Z., Gan, L., Zhang, Z., & Xie, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105490 · Cited by 59
Joseph, R. W., Peddareddigari, V. R., Liu, P., Miller, P. W., Overwijk, W. W., Bekele, N. B., Ross, M. I., Lee, J. E., Gershenwald, J. E., Lucci, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2769 · Cited by 55
Koganemaru, S., Inoshita, N., Miura, Y., Miyama, Y., Fukui, Y., Ozaki, Y., Tomizawa, K., Hanaoka, Y., Toda, S., Suyama, K., et al. (2017) · Cancer Science · doi:10.1111/cas.13229 · Cited by 55
Katayama (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.949 · Cited by 56
Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
Saito, H., Kono, Y., Murakami, Y., Shishido, Y., Kuroda, H., Matsunaga, T., Fukumoto, Y., Osaki, T., Ashida, K., & Fujiwara, Y. (2018) · Anticancer Research · doi:10.21873/anticanres.12197 · Cited by 57
New clinical advances in immunotherapy for the treatment of solid tumours
Zavala, V. A., & Kalergis, A. M. (2015) · Immunology · doi:10.1111/imm.12459 · Cited by 56
Wang, Z., Peng, S., Xie, H., Guo, L., Cai, Q., Shang, Z., Jiang, N., & Niu, Y. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-018-0488-3 · Cited by 58
Thompson, R. H., Webster, W. S., Cheville, J. C., Lohse, C. M., Dong, H., Leibovich, B. C., Kuntz, S. M., Sengupta, S., Kwon, E. D., & Blute, M. L. (2005) · Urology · doi:10.1016/j.urology.2005.06.010 · Cited by 55
Self-citationWang, L., Li, J., Li, P., Zhang, X., Chen, J., Qiu, H., Wu, X., & Zhang, B. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s84234 · Cited by 54
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some
Rowdo, F. P. M., Barón, A., Urrutia, M., & Mordoh, J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00127 · Cited by 55
Varki, V., Ioffe, O. B., Bentzen, S. M., Heath, J., Cellini, A., Feliciano, J. L., & Zandberg, D. P. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2138-8 · Cited by 56
Zhang, L., Yu, Z., Tu, Q., Xue, X., Zhu, X., & Zhao, K. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200128105459 · Cited by 56
Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
Tucker, M. D., & Rini, B. I. (2020) · Cancers · doi:10.3390/cancers12092662 · Cited by 56
Shu, Z., Dwivedi, B., Switchenko, J. M., Yu, D. S., & Deng, X. (2024) · Nature Communications · doi:10.1038/s41467-024-51242-8 · Cited by 54
PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond
Harshman, L. C., Drake, C. G., & Choueiri, T. K. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0193 · Cited by 51
Takada, K., Kashiwagi, S., Goto, W., Asano, Y., Takahashi, K., Takashima, T., Tomita, S., Ohsawa, M., Hirakawa, K., & Ohira, M. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1460-4 · Cited by 53
Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
Ding, X., Chen, Q., Yang, Z., Li, J., Zhan, H., Lu, N., Chen, M., Yang, Y., Wang, J., & Yang, D. (2019) · Cancer Management and Research · doi:10.2147/cmar.s176937 · Cited by 56
Immunobiology of Cancer Therapies Targeting CD137 and B7-H1/PD-1 Cosignal Pathways
Wang, S., & Chen, L. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_81 · Cited by 53
Self-citationTel, J., Hato, S. V., Torensma, R., Buschow, S. I., Figdor, C. G., Lesterhuis, W. J., & de Vries, I. J. M. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1189-x · Cited by 51
Bigelow, E. O., Bever, K. M., Xu, H., Yager, A., Wu, A. A., Taube, J. M., Chen, L., Jaffee, E. M., Anders, R. A., & Zheng, L. (2013) · Journal of Visualized Experiments · doi:10.3791/4059 · Cited by 49
Self-citationImmunotherapeutic strategies in kidney cancer—when TKIs are not enough
Biswas, S., & Eisen, T. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.91 · Cited by 49
Clinical Significance of the Costimulatory Molecule B7-H1 in Barrett Carcinoma
Loos, M., Langer, R., Schuster, T., Gertler, R., Walch, A. K., Rauser, S., Frieß, H., & Feith, M. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2010.12.041 · Cited by 50
Sanjmyatav, J., Steiner, T., Wunderlich, H., Diegmann, J., Gajda, M. R., & Junker, K. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.03.033 · Cited by 47
Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia
Knaus, H. A., Kanakry, C. G., Luznik, L., & Gojo, I. (2017) · Current Drug Targets · doi:10.2174/1389450116666150518095346 · Cited by 53
Mkrtichyan, M., Najjar, Y. G., Raulfs, E. C., Liu, L., Langerman, S., Guittard, G., Ozbun, L., & Khleif, S. N. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103085 · Cited by 46
Therapeutic Antibodies in Cancer Therapy
Gasser, M., & Waaga-Gasser, A. M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-32805-8_6 · Cited by 52
Monoclonal Antibody L 1 Mab-13 Detected Human PD-L1 in Lung Cancers
Yamada, S., Itai, S., Nakamura, T., Yanaka, M., Chang, Y.-W., Suzuki, H., Kaneko, M. K., & Kato, Y. (2018) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2018.0004 · Cited by 47
Control of the Adaptive Immune Response by Tumor Vasculature
Mauge, L., Terme, M., Tartour, É., & Helley, D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00061 · Cited by 49
Stromal and intraepithelial tumor‑infiltrating lymphocytes in colorectal carcinoma
Jakubowska, K., Kisielewski, W., Kańczuga‐Koda, L., Koda, M., & FAMULSKI, W. (2017) · Oncology Letters · doi:10.3892/ol.2017.7013 · Cited by 57
PD-L1 expression in malignant salivary gland tumors
Harada, K., Ferdous, T., & Ueyama, Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-4069-3 · Cited by 46
The prognostic significance of immune microenvironment in breast ductal carcinoma in situ
Toss, M. S., Abidi, A., Lesche, D., Joseph, C., Mahale, S., Saunders, H., Kader, T., Miligy, I. M., Green, A. R., Gorringe, K. L., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0797-7 · Cited by 52
Chen, J., Hu, X., Li, Q., Dai, W., Cheng, X., Huang, W. M., Yu, W., Chen, M., Guo, Y., & Yuan, G. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6063 · Cited by 46
RetractedThe impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy
Mortezaee, K., Majidpoor, J., & Kharazinejad, E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114646 · Cited by 48
Hendriks, D., He, Y. Z., Koopmans, I., Wiersma, V. R., van Ginkel, R. J., Samplonius, D. F., Helfrich, W., & Bremer, E. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1202390 · Cited by 49
Significance of B7-H1 Overexpression in Kidney Cancer
Thompson, R. H., & Kwon, E. D. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.n.038 · Cited by 48
Self-citationImmune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy
Andersen, M. H. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv154 · Cited by 46
PD‐1 expression on Melan‐A‐reactive T cells increases during progression to metastatic disease
Krönig, H., Falchner, K. J., Odendahl, M., Brackertz, B., Conrad, H., Muck, D., Hein, R., Blank, C. U., Peschel, C., Haller, B., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26272 · Cited by 47
PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence
Tykodi, S. S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s48443 · Cited by 45
Potential of New Therapies like Anti-PD1 in Kidney Cancer
Gunturi, A., & McDermott, D. F. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-013-0268-y · Cited by 47
Risk stratification and prognostication of renal cell carcinoma
Ficarra, V., Galfano, A., Novara, G., Iafrate, M., Brunelli, M., Secco, S., Cavalleri, S., Martignoni, G., & Artibani, W. (2008) · World Journal of Urology · doi:10.1007/s00345-008-0259-y · Cited by 51
Tan, S., Chen, D., Liu, K., He, M., Song, H., Shi, Y., Liu, J., Zhang, C. W.-H., Qi, J., Yan, J., et al. (2016) · Protein & Cell · doi:10.1007/s13238-016-0337-7 · Cited by 43
Joseph, R. W., Parasramka, M. A., Eckel‐Passow, J. E., Serie, D., Wu, K. J., Jiang, L., Kalari, K. R., Thompson, R. H., Ho, T. H., Castle, E. P., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0042 · Cited by 43
Self-citationLee, J., Kefford, R. F., & Carlino, M. S. (2016) · Immunotherapy · doi:10.2217/imt-2016-0022 · Cited by 44
Kouketsu, A., Sato, I., Oikawa, M., Shimizu, Y., Saito, H., Takahashi, T., & Kumamoto, H. (2017) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2017.04.013 · Cited by 47
Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma
Labriola, M., Batich, K. A., Zhu, J., McNamara, M. A., Harrison, M. R., Armstrong, A. J., George, D. J., & Zhang, T. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.01.017 · Cited by 42
Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma
Kahlmeyer, A., Stöhr, C., Hartmann, A., Goebell, P. J., Wullich, B., Wach, S., Taubert, H. W., & Erlmeier, F. (2018) · Journal of Clinical Medicine · doi:10.2139/ssrn.3284851 · Cited by 46
Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma
Petitprez, F., Ayadi, M., de Reyniès, A., Fridman, W. H., Sautès‐Fridman, C., & Job, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.643065 · Cited by 48
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview
Alme, A., Karir, B. S., Faltas, B. M., & Drake, C. G. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.01.006 · Cited by 45
Contemporary treatment of metastatic renal cell carcinoma
Stukalin, I., Alimohamed, N. S., & Heng, D. Y. C. (2016) · Oncology Reviews · doi:10.4081/oncol.2016.295 · Cited by 43
Immunotherapy for gastric cancers: emerging role and future perspectives
Bonotto, M., Garattini, S. K., Basile, D., Ongaro, E., Fanotto, V., Cattaneo, M., Cortiula, F., Iacono, D., Cardellino, G. G., Pella, N., et al. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1313113 · Cited by 44
Cedrés, S., Ponce-Aix, S., Pardo, N., Navarro, A., Martínez‐Martí, A., Zugazagoitia, J., Sansano, I., Montoro, M. A., Enguita, A. B., & Felip, E. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.03.001 · Cited by 46
PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis
Lin, Z., Chen, X., Li, Z., Luo, Y., Fang, Z., Xu, B., & Han, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160485 · Cited by 43
Robu, S., Richter, A., Gosmann, D., Seidl, C., Leung, D. K.-W., Hayes, W., Cohen, D., Morin, P. E., Donnelly, D. J., Lipovšek, D., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.258384 · Cited by 40
Costantini, F., & Barbieri, G. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.05.008 · Cited by 42
Parker, A. S., Heckman, M. G., Sheinin, Y. M., Wu, K. J., Hilton, T. W., Diehl, N. N., Pisansky, T. M., Schild, S. E., Kwon, E. D., & Buskirk, S. J. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.01.061 · Cited by 39
Self-citationTissue biomarkers in renal cell carcinoma: Issues and solutions
Napoli, A. D., & Signoretti, S. (2009) · Cancer · doi:10.1002/cncr.24233 · Cited by 42
CD4 T cell knockout does not protect against kidney injury and worsens cancer
Ravichandran, K., Wang, Q., Özkök, A., Jani, A. H., Li, H. Y., He, Z., Ljubanović, D. G., Weiser‐Evans, M. C. M., Nemenoff, R. A., & Edelstein, C. L. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1366-z · Cited by 39
Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma
Gulati, S., Barata, P. C., Elliott, A., Bilen, M. A., Burgess, E. F., Choueiri, T. K., Darabi, S., Dawson, N. A., Gartrell, B. A., Hammers, H. J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176230 · Cited by 40
Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma.
Zhu, H., Qin, H., Huang, Z., Li, S., Zhu, X., He, J., Yang, J. L., Yu, X., & Yi, X. (2015) · PubMed · Cited by 42
Immune Checkpoint Therapy in Renal Cell Carcinoma
Lee, C., & Motzer, R. J. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000177 · Cited by 40
Nishimori, A., Konnai, S., Okagawa, T., Maekawa, N., Ikebuchi, R., Goto, S., Sajiki, Y., Suzuki, Y., Kohara, J., Ogasawara, S., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174916 · Cited by 44
PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma
Carlsson, J., Sundqvist, P., Kosuta, V., Fält, A., Giunchi, F., Fiorentino, M., & Davidsson, S. (2019) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000766 · Cited by 40
Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy
Mauzo, S. H., Tetzlaff, M. T., Milton, D. R., Siroy, A. E., Nagarajan, P., Torres-Cabala, C. A., Ivan, D. S., Curry, J. L., Hudgens, C. W., Wargo, J. A., et al. (2019) · Cancers · doi:10.3390/cancers11060754 · Cited by 38
Shrestha, R., Bridle, K. R., Crawford, D. H., & Jayachandran, A. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.10991 · Cited by 40
Shen, M., Chen, G., Xie, Q., Li, X., Xu, H., Wang, H., & Zhao, S. (2020) · Urologia Internationalis · doi:10.1159/000506296 · Cited by 40
Immune suppression in renal cell carcinoma
Frankenberger, B., Noeßner, E., & Schendel, D. J. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.004 · Cited by 40
TLR-mediated induction of negative regulatory ligands on dendritic cells
Gröschel, S., Piggott, K., Vaglio, A., Ma-Krupa, W., Singh, K., Goronzy, J. J., & Weyand, C. M. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0310-x · Cited by 40
Borch, T. H., Donia, M., Andersen, M. H., & Svane, I. M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.003 · Cited by 40
Immunotherapy for Renal Cell Carcinoma
Rosenblatt, J. M., & McDermott, D. F. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.04.010 · Cited by 40
PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine
Ahmad, S. M., Martinenaite, E., Hansen, M., Junker, N., Borch, T. H., Met, Ö., Donia, M., Svane, I. M., & Andersen, M. H. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1202391 · Cited by 37
Martín‐Sánchez, D., Fontecha‐Barriuso, M., Sánchez-Niño, M. D., Ramos, A. M., Benavente, R. C., Enguita, C. G., Linkermann, A., Sanz, A. B., & Ortíz, A. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0043-2 · Cited by 38
Zhang, S., Zhang, M., Wu, W., Yuan, Z., Tsun, A., Wu, M. H., Chen, B., Jia, L., Miao, X., Miao, X., et al. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby005 · Cited by 37
Messeha, S. S., Zarmouh, N. O., & Soliman, K. F. A. (2021) · Nutrients · doi:10.3390/nu13051718 · Cited by 37
Nivolumab in the treatment of malignant melanoma: review of the literature
Nakamura, M., Mashima, E., Yamaguchi, T., Sasaki, N., Hara, Y., Omoto, D., Haruyama, S., Yoshioka, M., Nishio, D., Sakuragi, Y., et al. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s62102 · Cited by 39
Jang, B., & Kim, I. A. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.05.009 · Cited by 36
Immune expression in children with Wilms tumor: a pilot study
Holl, E. K., Routh, J. C., Johnston, A. W., Frazier, V., Rice, H. E., Tracy, E. T., & Nair, S. K. (2019) · Journal of Pediatric Urology · doi:10.1016/j.jpurol.2019.03.011 · Cited by 37
Targeting the programmed death-1 pathway in lymphoid neoplasms
Ok, C. Y., & Young, K. H. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.009 · Cited by 39
Clinical and Molecular Prognostic Factors in Renal Cell Carcinoma: What We Know So Far
Tang, P. A., Vickers, M. M., & Heng, D. Y. C. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.04.003 · Cited by 35
Rimar, K. J., Meeks, J. J., & Kuzel, T. M. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.02.013 · Cited by 34
Wang, W., Lam, W., & Chen, L. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2260-7 · Cited by 34
Self-citationPDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma
Billon, E., Finetti, P., Bertucci, A., Niccoli, P., Birnbaum, D., Mamessier, É., & Bertucci, F. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1655362 · Cited by 37
Alaghehbandan, R., Stehlík, J., Trpkov, K., Magi‐Galluzzi, C., Condom, E., Pané, M., Berney, D. M., Sibony, M., Suster, S. M., Agaimy, A., et al. (2017) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2017.04.007 · Cited by 35
Chakravarti, N., & Prieto, V. G. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.12.10 · Cited by 39
B7-H1 as a Biomarker for Therapy Failure in Patients with Favorable Histology Wilms Tumor
Routh, J. C., Grundy, P. E., Anderson, J. R., Retik, A. B., & Kurek, K. C. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.11.012 · Cited by 33
Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes
Horn, L. A., Long, T. M., Atkinson, R. S., Clements, V. K., & Ostrand‐Rosenberg, S. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0026 · Cited by 38
Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy
Lecis, D., Sangaletti, S., Colombo, M. P., & Chiodoni, C. (2019) · Cancers · doi:10.3390/cancers11050624 · Cited by 37
Wu, Y.-H., Chen, R.-J., Chiu, H., Yang, L., Wang, Y., Chen, Y., Yeh, Y.-L., Liao, M., & Wang, Y. (2022) · Theranostics · doi:10.7150/thno.77233 · Cited by 33
Current developments with peptide-based human tumor vaccines
Khazaie, K., Bonertz, A., & Beckhove, P. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328331a78e · Cited by 37
Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition
Sodji, Q. H., Klein, K., Kavuri, S., & Parikh, J. R. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0267-9 · Cited by 32
Doğan, H. T., Kıran, M. M., Bilgin, B., Kılıçarslan, A., Şendur, M. A. N., Yalçın, B., Ardıçoğlu, A., Atmaca, A. F., & Gümüşkaya, B. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0742-8 · Cited by 33
Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date
Tacconi, E. M., Tuthill, M. H., & Protheroe, A. S. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s174149 · Cited by 35
Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview
Kejamurthy, P., & Devi, K. T. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02267-4 · Cited by 32
Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience
Mennitto, A., Grassi, P., Ratta, R., Verzoni, E., Prisciandaro, M., & Procopio, G. (2016) · Therapeutic Advances in Urology · doi:10.1177/1756287216656811 · Cited by 30
Metadata
- Authors
- Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., Zincke, H., Blute, M. L., Strome, S. E., Leibovich, B. C., & Kwon, E. D.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2004-11-29
- Volume
- 101
- Issue
- 49
- Pages
- 17174-17179
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC534606
- OpenAlex
- W4230861071
- Cited by
- 776
- References
- 48
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 15 · 2023: 29 · 2022: 32 · 2021: 42 · 2020: 51 · 2019: 60 · 2018: 57 · 2017: 76 · 2016: 65 · 2015: 69 · 2014: 57 · 2013: 29 · 2012: 28
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, renal cell carcinoma, tumor-infiltrating lymphocytes, tumor progression, prognostic factors, tumor immune evasion, T cell costimulation, immunotherapy targets, cancer mortality
- MeSH terms
- Carcinoma, Renal Cell, Follow-Up Studies, Humans, Immunity, Immunohistochemistry, Membrane Glycoproteins, Neoplasm Proteins, Peptides, Prognosis, Antigens, CD, Odds Ratio, Survival Analysis, Lymphocytes, Tumor-Infiltrating, B7-1 Antigen, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.